"A+H双市套利"背后的困惑:百奥赛图募资初衷与上市规划,为何难逃业界的深层质疑?

中金在线
Sep 23

百奥赛图(北京)医药科技股份有限公司(以下简称“百奥赛图”)将于2025 年9 月24日上会接受上交所审核。其募资规模从18.93亿元骤缩至11.85亿元,这种融资规模的异常调整,揭开了这家 生物医药 企业利用两地资本市场制度差异进行融资套利的冰山一角。深入分析其港股与 A 股上市的募资计划、资金用途及时间节点发现,公司隐藏着缓解资金链紧张、掩盖研发乏力以及实控人债务危机的情况。其中募资用途从研发...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10